ResultsIQ

ResultsIQ › Latest results › Bharat Parenterals Limited

Bharat Parenterals Limited Q2 FY27 earnings call summary

NSE: BPLPHARMA · BSE: 541096

Earnings call of 30 Oct 2026, summarised by AI from the filing.

Bharat Parenterals swung to a consolidated PAT of ₹11.8 cr in Q2 FY27 as Innoxel reached a 33% EBITDA margin and FY27 guidance was maintained.

Key takeaways

  1. Innoxel swing Innoxel EBITDA ₹14.6 cr at 33% margin against a loss of ₹1.8 cr in Q1 FY27.
  2. US supply First CMO product exported to the US on 20 October 2026, moving Innoxel into recurring commercial supply.
  3. Input costs Rising input costs cut standalone gross margin to 35% and pressure margins on orders priced earlier.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.